X4 Pharmaceuticals Appoints William E. Aliski to Board of Directors
“Bill’s broad knowledge and demonstrated success across many areas of commercial activity will be invaluable to X4 as we continue to execute our Phase 3 clinical trial in WHIM syndrome and lay a strong foundation to build out our commercial infrastructure,” said
“I am excited to join this accomplished and committed team of industry leaders as we work together to bring novel therapies to patients with rare diseases who need more effective treatment options. I look forward to contributing my expertise as X4 pursues a potential first-in-class therapy for WHIM syndrome and prepares for commercialization,” commented Mr. Aliski.
Since 2011, Mr. Aliski has served as an independent consultant to life sciences companies focused on orphan diseases, with particular focus on commercial strategy, market access, pricing, and reimbursement. Prior to 2011, he was Chief Commercial Officer for
In addition to Mr. Aliski’s current Board appointments, he previously served on the Boards of
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include, but are not limited to, statements regarding X4’s business strategy, including its clinical development plans and preparations to commercialize its product candidates. These statements are subject to various risks and uncertainties, actual results could differ materially from those projected, and X4 cautions investors not to place undue reliance on the forward-looking statements in this press release. These risks and uncertainties include, without limitation, the risk that any one or more of X4’s product candidates will not be successfully developed, approved or commercialized, the risk that X4’s ongoing or planned clinical trials and studies may be delayed, and the risk that costs required to develop X4’s product candidates or to expand its operations will be higher than anticipated. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in X4’s most recent Annual Report on Form 10-K filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20190923005221/en/
Source:
Investors:
Stephanie Carrington
Westwicke, an ICR company
646-277-1282
Stephanie.Carrington@icrinc.com
Media:
Darcie Robinson
Westwicke, an ICR company
203-919-7905
Darcie.robinson@icrinc.com